Applied Therapeutics’ (APLT) “Neutral” Rating Reaffirmed at UBS Group

UBS Group reaffirmed their neutral rating on shares of Applied Therapeutics (NASDAQ:APLT) in a report published on Monday, Marketbeat reports. UBS Group currently has a $2.00 target price on the stock, down from their prior target price of $13.00.

A number of other equities analysts have also issued reports on APLT. Royal Bank of Canada lowered shares of Applied Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $12.00 to $4.00 in a research report on Friday. William Blair raised shares of Applied Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup reduced their target price on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a report on Friday. Leerink Partners raised their price target on Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Finally, Robert W. Baird reduced their price objective on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Applied Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $6.60.

Applied Therapeutics Stock Performance

APLT opened at $1.75 on Monday. Applied Therapeutics has a one year low of $1.68 and a one year high of $10.62. The stock has a market capitalization of $203.63 million, a P/E ratio of -1.09 and a beta of 2.01. The business’s 50-day simple moving average is $8.59 and its 200-day simple moving average is $6.45.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $54,000. Principal Financial Group Inc. acquired a new stake in Applied Therapeutics in the second quarter valued at $54,000. SG Americas Securities LLC purchased a new stake in shares of Applied Therapeutics during the 2nd quarter worth $87,000. Algert Global LLC acquired a new position in shares of Applied Therapeutics during the 2nd quarter worth $110,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Applied Therapeutics in the 3rd quarter valued at about $149,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.